Cystic Fibrosis Drug Shows Rapid Benefits

News | Health

A rigorous study concludes that experimental medication improved lung function and weight gain

By Christine Gorman ?| November 2, 2011

CHRONIC LUNG DISEASE: People with cystic fibrosis are more prone to infections with bacteria such as Pseudomonas aeruginosa (shown). Image: CDC

People with an uncommon form of cystic fibrosis started gaining weight and were better able to breathe than their untreated counterparts after just two weeks on an experimental drug, according to a study published November 2 in the New England Journal of Medicine. If approved by the U.S. Food and Drug Administration, the drug, once known as VX-770 and now called ivacaftor, would be the first medication to target the underlying protein defect that causes the disease.

The findings are particularly compelling because the drug's benefits lasted for the duration of the 48-week randomized double-blind, placebo-controlled trial (the most rigorous type of scientific investigation that can be conducted).

In addition, clinicians have long known that cystic fibrosis patients with stable lung function who do not lose weight are more likely to live longer. That does not necessarily prove that ivacaftor can improve lifespan, but the possibility is tantalizing. "I've been involved in clinical trials for 30 years," says the study's lead author Bonnie Ramsey, a professor of pediatrics at the University of Washington School of Medicine in Seattle. "I've never seen this kind of change that has been sustained this long."

An estimated 70,000 individuals around the globe suffer from cystic fibrosis (CF), which interferes with the normal function of the respiratory and digestive systems. The particular protein defect that the drug is designed to counteract affects about 5 percent of all CF patients. With good preventive care and treatment, the majority of all CF patients are able to live to their late 30s or early 40s.

To learn more, read Scientific American?s feature "A Breath of Fresh Air" (preview), about the research behind ivacaftor and several other compounds that may someday address more common forms of cystic fibrosis.

Source: http://rss.sciam.com/click.phdo?i=c292e299dd30c999a906bbe46db93ac4

chris morris mike stoops mike stoops end of the world end of the world jerome harrison ryan leaf